Table 3.

Response of transduced IMR-32 and IMR/KAT100 cells to cytotoxic drugs in 72-h cytotoxicity assays

DrugCell lineFold resistance *PCell lineFold resistance *PCell lineFold sensitization P§
DoxorubicinIMR/LXSPIMR/shGFPIMR/KAT100/shGFP
IMR/GSE562.460.045IMR/shp533.100.004IMR/KAT100/shp530.57NS
VincristineIMR/LXSPIMR/shGFPIMR/KAT100/shGFP
IMR/GSE561.640.039IMR/shp533.620.036IMR/KAT100/shp530.85NS
VM26IMR/LXSPIMR/shGFPIMR/KAT100/shGFP
IMR/GSE561.630.013IMR/shp531.510.002IMR/KAT100/shp530.13NS
CisplatinIMR/LXSPIMR/shGFPIMR/KAT100/shGFP
IMR/GSE563.920.001IMR/shp533.010.004IMR/KAT100/shp530.45NS
KATIMR/LXSPIMR/shGFP
IMR/GSE561.290.024IMR/shp531.310.024
MelphalanIMR/LXSPIMR/shGFP
IMR/GSE5620.19<0.001IMR/shp53
TaxolIMR/LXSPIMR/shGFP
IMR/GSE562.29NSIMR/shp531.72NS
  • * The fold resistance was determined by dividing the ID50 of IMR/GSE56 or IMR/shp53 cells by that of control IMR/LXSP or IMR/shGFP cells, respectively.

  • For a given drug, P values were determined by comparing the ID50 value for IMR/GSE56 or IMR/shp53 cells with the ID50 value of their corresponding control cells assayed in the same series of experiments.

  • The fold sensitization was calculated by dividing the mean ID50 for the control IMR/KAT100/shGFP cells by the mean ID50 for the IMR/KAT100/shp53 cells.

  • § For a given drug, P valves were determined by comparing the ID50 value for IMR/KAT100/shGFP cells with the ID50 value of IMR/KAT100/shp53 cells assayed in the same series of experiments.